Stockscreener 앱 받기
4.08
2.39%
-0.10
시간 외 거래:
4.10
0.02
+0.49%
전일 마감가:
$4.18
열려 있는:
$4.2
하루 거래량:
2.38M
Relative Volume:
0.37
시가총액:
$888.23M
수익:
$76.20M
순이익/손실:
$-17.37M
주가수익비율:
448.35
EPS:
0.0091
순현금흐름:
$-75.81M
1주 성능:
-0.97%
1개월 성능:
-10.53%
6개월 성능:
-3.09%
1년 성능:
+324.47%
1일 변동 폭
$4.04
$4.255
1주일 범위
$3.99
$4.38
52주 변동 폭
$0.9041
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.08 | 910.00M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 재개 | Barclays | Overweight |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
MSN Money - MSN
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Certain Restricted Stock Units of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com
170,186,365 Common Stock of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com
CytomX (NASDAQ: CTMX) proxy adds share capacity and expands equity plans - Stock Titan
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo Finance UK
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - MSN
CytomX stock rises 31% in a month: Here's what you should know - MSN
Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN
CytomX Therapeutics launches $250M public offering - MSN
Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
CTMX (CytomX Therapeutics Inc.) shares climb over 7 percent despite wider than expected Q4 2025 per share losses.Margin of Safety - Cổng thông tin điện tử tỉnh Tây Ninh
Small Cap or Megacap: Which Healthcare Stock Is Right for You? - The Motley Fool
CTMX Forecast, Price Target & Analyst Ratings | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN
CytomX (NASDAQ: CTMX) seeks shareholder OK to double authorized shares to 600M - Stock Titan
CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN
HC Wainwright & Co. Maintains CytomX Therapeutics (CTMX) Buy Recommendation - MSN
CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN
CytomX Therapeutics Inc Share PriceCTMX, RNS News, Articles, Quotes, & Charts (NASDAQ:CTMX) - Proactive financial news
CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why CTMX Stock Is Soaring 54% Pre-Market Today? - MSN
Point72 (CTMX) reports 10,864,581 shares, a 5.0% holding in CytomX - Stock Titan
Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%Time to Buy? - MarketBeat
CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a 199.71% Potential Upside in the Biotech Innovator - DirectorsTalk Interviews
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress - Insider Monkey
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):